{"title":"第22届欧洲心胸麻醉师协会年会摘要。","authors":"F. Szlam, G. Dickneite, J. Levy, K. Tanaka","doi":"10.1017/s0265021507001068","DOIUrl":null,"url":null,"abstract":"Silesian Centre for Heart Diseases, Zabrze, Poland Introduction: Diabetic patients have poorer short-term outcome after coronary artery surgery [1]. It has been suggested that preoperative HbA1c may predict length of stay in such patients [2]. The aim of this study was to find out the impact of long-term glycaemic control expressed by preoperative HbA1c on perioperative outcome in diabetic patients following coronary artery surgery. Method: 145 consecutive diabetic patients underwent first-time coronary artery surgery in a period of 11 months and had their HbA1c assessed Results: Fifty-nine percent of the patients had low plasma AT III levels before CPB (levels 80%). Of these, 64% required the administration of AT III concentrate for correct anticoagulation to be attained, since the mean ACT after the first dose of heparin was 404 seconds. In 37.5% of the cases, the patients received 500 U of AT III; 12.5% 750 U of AT III, and 50% 1000 U of AT III. Conclusions: We consider that a low pre-operative plasma AT III level predicts and an ACT value lower than 480 seconds after heparin indicates resistance to heparin and the need to administer AT III concentrate to achieve correct anticoagulation during CPB. The optimum dose of AT III concentrate in cases of heparin resistance is 1000 U.","PeriodicalId":11873,"journal":{"name":"European journal of anaesthesiology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstracts of the 22nd Annual Meeting of the European Association of Cardiothoracic Anaesthesiologists.\",\"authors\":\"F. Szlam, G. Dickneite, J. Levy, K. Tanaka\",\"doi\":\"10.1017/s0265021507001068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Silesian Centre for Heart Diseases, Zabrze, Poland Introduction: Diabetic patients have poorer short-term outcome after coronary artery surgery [1]. It has been suggested that preoperative HbA1c may predict length of stay in such patients [2]. The aim of this study was to find out the impact of long-term glycaemic control expressed by preoperative HbA1c on perioperative outcome in diabetic patients following coronary artery surgery. Method: 145 consecutive diabetic patients underwent first-time coronary artery surgery in a period of 11 months and had their HbA1c assessed Results: Fifty-nine percent of the patients had low plasma AT III levels before CPB (levels 80%). Of these, 64% required the administration of AT III concentrate for correct anticoagulation to be attained, since the mean ACT after the first dose of heparin was 404 seconds. In 37.5% of the cases, the patients received 500 U of AT III; 12.5% 750 U of AT III, and 50% 1000 U of AT III. Conclusions: We consider that a low pre-operative plasma AT III level predicts and an ACT value lower than 480 seconds after heparin indicates resistance to heparin and the need to administer AT III concentrate to achieve correct anticoagulation during CPB. The optimum dose of AT III concentrate in cases of heparin resistance is 1000 U.\",\"PeriodicalId\":11873,\"journal\":{\"name\":\"European journal of anaesthesiology. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of anaesthesiology. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/s0265021507001068\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of anaesthesiology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/s0265021507001068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
导言:糖尿病患者冠状动脉手术后短期预后较差[1]。有研究认为术前HbA1c可以预测此类患者的住院时间[2]。本研究旨在探讨术前HbA1c表达的长期血糖控制对冠状动脉手术后糖尿病患者围手术期预后的影响。方法:145例连续11个月接受首次冠状动脉手术的糖尿病患者进行HbA1c评估。结果:59%的患者在CPB前血浆AT III水平较低(水平为80%)。其中,64%的患者需要使用AT III浓缩物才能获得正确的抗凝,因为第一次给药肝素后的平均ACT为404秒。37.5%的患者接受500u AT III;12.5% 750 U AT III, 50% 1000 U AT III。结论:我们认为术前血浆AT III水平低预示着肝素治疗后480秒内ACT值低于肝素治疗后480秒内ACT值表明患者对肝素有抵抗,需要给予AT III浓缩物以达到CPB期间正确的抗凝效果。在肝素耐药病例中,atiii浓缩物的最佳剂量为1000 U。
Abstracts of the 22nd Annual Meeting of the European Association of Cardiothoracic Anaesthesiologists.
Silesian Centre for Heart Diseases, Zabrze, Poland Introduction: Diabetic patients have poorer short-term outcome after coronary artery surgery [1]. It has been suggested that preoperative HbA1c may predict length of stay in such patients [2]. The aim of this study was to find out the impact of long-term glycaemic control expressed by preoperative HbA1c on perioperative outcome in diabetic patients following coronary artery surgery. Method: 145 consecutive diabetic patients underwent first-time coronary artery surgery in a period of 11 months and had their HbA1c assessed Results: Fifty-nine percent of the patients had low plasma AT III levels before CPB (levels 80%). Of these, 64% required the administration of AT III concentrate for correct anticoagulation to be attained, since the mean ACT after the first dose of heparin was 404 seconds. In 37.5% of the cases, the patients received 500 U of AT III; 12.5% 750 U of AT III, and 50% 1000 U of AT III. Conclusions: We consider that a low pre-operative plasma AT III level predicts and an ACT value lower than 480 seconds after heparin indicates resistance to heparin and the need to administer AT III concentrate to achieve correct anticoagulation during CPB. The optimum dose of AT III concentrate in cases of heparin resistance is 1000 U.